Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print New Vaccine Developed for Preventing 'Uncommon Cold' Virus

New Vaccine Developed for Preventing 'Uncommon Cold' Virus

February 03, 2009

FAIRFAX, Va.-Common colds typically cause a week of sneezing, aches and pains and then fade away leaving only a sore nose and a few used sick days behind. But what if that cold turned out to be something more?

Human adenovirus type-3 is known as the "uncommon cold" because the infection's symptoms-runny nose, sore throat, cough and fever-are eerily similar to those of the common cold which is caused by the rhinovirus. The difference is that, unlike the common cold, the symptoms of the uncommon cold are typically much more severe and can even be fatal.




Adenovirus-3 thrives in nations with dense urban populations and has recently become prevalent in southern China and neighboring countries. It may also emerge in less likely locales with dense populations, such as schools, health care facilities and military training bases in the U.S.

Determined to stamp out this devastating infection, researchers from George Mason University, the University of Hong Kong, Guangzhou Children's Hospital, the South China Institute of Technology and the Graduate School of Chinese Academy of Sciences have developed a DNA-based vaccine that has effectively protected mice from the infection.

Their findings will appear in the February 18, 2009 print edition of the journal Vaccine and are currently available online.

"Further study is required, but we hope that in the future, this simple, stable and inexpensive vaccine can be mass-produced and made available to susceptible populations," says Donald Seto, associate professor in George Mason University's Department of Bioinformatics and Computational Biology, the only U.S.-based researcher involved in the study. "Affordability is a key factor since these regions are generally economically depressed."

According to the Centers for Disease Control and Prevention (CDC), the human adenovirus was first seen in the 1950s and is associated with a wide spectrum of illnesses including conjunctivitis, upper respiratory infections, pneumonia and gastrointestinal disease. More than 50 unique serotypes of the virus have been identified, with even more expected to be isolated.

Adenovirus outbreaks are difficult to control because the virus can live for weeks on environmental surfaces and spreads quickly through direct contact, aerosol and contaminated drinking water.

Although the disease is relatively rare in the U.S., CDC records indicate that it has made several appearances here with devastating results. In 2000, four children died during an outbreak of adenovirus type-7 that occurred at a long-term care facility in Iowa, and nine patients died when adenovirus type-14 appeared as epidemics in Oregon, Texas and Washington in 2007.

Seto hopes that this new vaccine will serve as a model that allows his team to target the remaining strains of the virus.

"The immediate impact is the production and distribution of a low-cost, stable vaccine for adenovirus-3," says Seto. "The outstanding question is, if all of the strains are so similar, why are they restricted to certain tissues, like only the eyes or the respiratory tract? That's what we'll try to figure out next."

The paper was co-authored by Qiwei Zhang, Xiaobo Su, Bo-jian Zheng, Xingui Tian, Huiying Sheng, Haitao Li, Youshao Wang and Rong Zhou. The study was funded by the National Natural Science Foundation of China.

George Mason University



Related Adenovirus Current Events and Adenovirus News Articles Adenovirus Current Events and Adenovirus News RSS Adenovirus Current Events and Adenovirus News RSS
Penn-Wistar team gains insight into HIV vaccine failure
A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines.

Study offers insights into failed HIV-1 vaccine trial
Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection.

Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
Pancreatic cancer is a devastating disease with poor prognosis. This warrants the development of novel therapies including gene therapy.

Protein analysis methods, viral vectors featured in Cold Spring Harbor Protocols
Many proteins do not function by themselves as stand-alone units. Instead, multiple proteins associate to form larger structures called protein complexes.

Gene therapy appears safe to regenerate gum tissue
Scientists at the University of Michigan have developed a method of gene delivery that appears safe for regenerating tooth-supporting gum tissue-a discovery that assuages one of the biggest safety concerns surrounding gene therapy research and tissue engineering.

MDC researchers prevent virus induced myocarditis
Life-threatening cardiac arrhythmia can be a consequence of myocarditis - an inflammation of the cardiac muscle that can be caused by the Coxsackievirus.

TB vaccine developed at McMaster University in Canada
McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

Boosting its infectivity turns benign virus into good gene therapy carrier for cystic fibrosis
Researchers from the University of California, Berkeley, and the University of Iowa have turned a relatively benign virus into a highly infectious form that is ideal as a carrier for gene therapy.

Potential new herpes therapy studied
A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

Nose-spray vaccine against botulism effective in first tests
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy.
More Adenovirus Current Events and Adenovirus News Articles
Adenovirus: Webster's Timeline History, 2003 - 2007

Adenovirus: Webster's Timeline History, 2003 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Adenovirus," including when used in literature (e.g. all authors that might have Adenovirus in their name). As such, this book represents the largest compilation of timeline events associated with Adenovirus when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...

Zometool - Animal Virus

Zometool - Animal Virus
by Zometool

A virus is a mobile, teeny munitions plant for reproducing weapons of micro-destruction, This "bio-crystal" is smaller than a spec of dust and inert as a rock until it starts to wreak havoc by draining your life force to clone itself with robotic precision!

  Infectious Disease Tests & Controls, Adenovirus Tests - Viral Infection Tests & Control Sets
by SA Scientific

These rapid diagnostic tests are designed to facilitate the detection of a variety of viral and bacterial infectious diseases. Three viral infection tests are available: adenovirus, which can detect all 41 known adenovirus strains; rotavirus, which can detect all rotavirus strains; and RSV, which can detect the respiratory syncytial virus. Controls to validate results must be purchased separately. Tests are conducted by adding specimen samples into sample wells and simply reading results, which are available within 15 minutes. The bacterial infection StrepAlert test provides an immunoassay for Strep A. Controls are included with this test. The procedure is conducted with a dipstick and provides results within five minutes.

  Systemic infection with enteric adenovirus in immunocompetent child with Haemophilus influenzae disease.(LETTERS)(Letter to the editor): An article from: Emerging Infectious Diseases
by Nino Khetsuriani (Author), Suxiang Tong (Author), Xiaoyan Lu (Author), Shannon Reed (Author), Dean Erdman (Author), Angela Campbell (Author), Krongkaew Supawat (Author), Sahas Liamsuwan (Author), Narayanan Jothikumar (Author), Sonja Olsen (Author)

This digital document is an article from Emerging Infectious Diseases, published by U.S. National Center for Infectious Diseases on February 1, 2009. The length of the article is 1619 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Systemic infection with enteric adenovirus in immunocompetent child with Haemophilus influenzae disease.(LETTERS)(Letter to the editor)
Author: Nino Khetsuriani
Publication: Emerging Infectious Diseases (Magazine/Journal)
Date: February 1, 2009
Publisher: U.S. National Center for Infectious Diseases
Volume: 15 Issue: 2 Page: 355(3)

Article Type: Letter to the...

Progard KC Plus 25 dose

Progard KC Plus 25 dose
by Intervet Inc

Canine Adenovirus Type 2, Parainfluenza Modified Live, Bordetella Bronchiseptica vaccine. One nostril administration of a 0.4mL dose in healthy puppies as young as 3 weeks of age. Vaccinate prior to confinement or when risk of kennel cough exists. No applicator tip needed. Revaccinate annually.

  Adenovirus type 7 peptide diversity during outbreak, Korea, 1995-2000.(RESEARCH): An article from: Emerging Infectious Diseases
by Eun Hwa Choi (Author), Hee Sup Kim (Author), Byung Wook Eun (Author), Beyong, II Kim (Author), Jung Yeon Choi (Author), Hoan Jong Lee (Author), Toshiki Inada (Author)

This digital document is an article from Emerging Infectious Diseases, published by U.S. National Center for Infectious Diseases on May 1, 2005. The length of the article is 4850 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Adenovirus type 7 peptide diversity during outbreak, Korea, 1995-2000.(RESEARCH)
Author: Eun Hwa Choi
Publication: Emerging Infectious Diseases (Refereed)
Date: May 1, 2005
Publisher: U.S. National Center for Infectious Diseases
Volume: 11 Issue: 5 Page: 649(6)

Distributed by Thomson...

  Infectious obesity: adenovirus fattens stem cells.(This Week): An article from: Science News
by B. Vastag (Author)

This digital document is an article from Science News, published by Thomson Gale on August 25, 2007. The length of the article is 483 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infectious obesity: adenovirus fattens stem cells.(This Week)
Author: B. Vastag
Publication: Science News (Magazine/Journal)
Date: August 25, 2007
Publisher: Thomson Gale
Volume: 172 Issue: 8 Page: 115(2)

Distributed by Thomson...

Galaxy DA2PPvL+Cv 25 dose

Galaxy DA2PPvL+Cv 25 dose
by Schering Plough Animal Health Co

Canine Distemper, Adenovirus-2, Parainfluenza, Parvo MLV, Corona Killed, Lepto Bacterin vaccine. Inject 1mL IM or SQ, to healthy dogs 6 weeks of age or older, repeat every 2-4 weeks until 12 weeks of age. Minimum of 2 doses is required for primary immunization. Do not vaccinate pregnant bitches. Revaccinate annually.

Adenovirus-Mediated: Webster's Timeline History, 1991 - 2007

Adenovirus-Mediated: Webster's Timeline History, 1991 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Adenovirus-Mediated," including when used in literature (e.g. all authors that might have Adenovirus-Mediated in their name). As such, this book represents the largest compilation of timeline events associated with Adenovirus-Mediated when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture,...

  Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.: An article from: Emerging Infectious Diseases
by Zhiquan Xiang (Author), Yan Li (Author), Ann Cun (Author), Wei Yang (Author), Susan Ellenberg (Author), William M. Switzer (Author), Marcia L. Kalish (Author), Hildegund C.J. Ertl (Author)

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on October 1, 2006. The length of the article is 2643 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.
Author: Zhiquan Xiang
Publication: Emerging Infectious Diseases (Magazine/Journal)
Date: October 1, 2006
Publisher: Thomson Gale
Volume: 12 Issue: 10 Page: 1596(4)

Distributed by Thomson...

© 2009 BrightSurf.com